These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 31254157)
1. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157 [TBL] [Abstract][Full Text] [Related]
2. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer. Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037 [TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929 [TBL] [Abstract][Full Text] [Related]
7. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells. Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841 [No Abstract] [Full Text] [Related]
9. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211 [TBL] [Abstract][Full Text] [Related]
11. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936 [TBL] [Abstract][Full Text] [Related]
12. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related]
13. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327 [TBL] [Abstract][Full Text] [Related]
14. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Ong CC; Jubb AM; Haverty PM; Zhou W; Tran V; Truong T; Turley H; O'Brien T; Vucic D; Harris AL; Belvin M; Friedman LS; Blackwood EM; Koeppen H; Hoeflich KP Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7177-82. PubMed ID: 21482786 [TBL] [Abstract][Full Text] [Related]
15. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer. Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164 [TBL] [Abstract][Full Text] [Related]
16. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750 [TBL] [Abstract][Full Text] [Related]
17. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553 [No Abstract] [Full Text] [Related]
18. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768 [TBL] [Abstract][Full Text] [Related]
19. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611 [TBL] [Abstract][Full Text] [Related]
20. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]